Kiniksa Pharmaceuticals International, plc Share-based Payment Arrangement, Expense, Tax Benefit
Kiniksa Pharmaceuticals International, plc (KNSA) reported Share-based Payment Arrangement, Expense, Tax Benefit of $9.64 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense · last filed 2026-02-24
- Kiniksa Pharmaceuticals International, plc share-based payment arrangement, expense, tax benefit for fiscal 2025 was $9.64M, a 20.90% increase from fiscal 2024.
- Kiniksa Pharmaceuticals International, plc share-based payment arrangement, expense, tax benefit for fiscal 2024 was $7.98M, a 7.31% increase from fiscal 2023.
- Kiniksa Pharmaceuticals International, plc share-based payment arrangement, expense, tax benefit for fiscal 2023 was $7.43M.
| Period end | Share-based Payment Arrangement, Expense, Tax Benefit 12 month |
|---|---|
| 2025-12-31 | $9.64M 10-K · filed 2026-02-24 |
| 2024-12-31 | $7.98M 10-K · filed 2026-02-24 |
| 2023-12-31 | $7.43M 10-K · filed 2026-02-24 |